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INTRODUCTION
Ceramides are the main lipids in the stratum corneum (1).
The depletion of ceramides in the stratum corneum is thought
to be one of the etiological factors producing dryness and
barrier disruption in skin conditions (2-4). Marked depletion
of ceramides in the stratum corneum has been reported in
patients with psoriasis.
Ceramides are generated during cellular stress and apop-
tosis by de novo synthesis or by the action of sphingomyeli-
nase. Ceramides have antiproliferative and apoptotic effects
(5). These are lipid second messengers produced by sphin-
golipid metabolism, and they trigger important cell responses,
including protein kinase C-alpha (PKC- ) activation (6).
Ceramides stimulate the signal transduction pathway with
apoptosis and activate stress-activated protein kinases (SAPK),
such as c-jun N-terminal kinase (JNK) (7).
Several investigators have already reported decreased levels
of epidermal ceramides in psoriasis. However, only limited
information is available on the alterations in the apoptotic
pathway related to ceramides in skin diseases with epider-
mal proliferation, including psoriasis. Therefore, this study
examined the alterations in the levels of epidermal ceramides
and ceramide-related apoptotic signaling molecules in patients
with psoriasis.
MATERIALS AND METHODS
Patients and skin biopsies
Five Korean patients with psoriasis (2 women, 3 men) rang-
ing in age from 19 to 33 yr gave informed consent and took
part in this study. All the subjects had psoriasis vulgaris as
identified through clinical and histological assessment and
had not been treated either systemically or topically for at
least 1 month before punch biopsies were obtained.
Using a 4-mm punch, biopsies were taken from lesional
and non-lesional skin on the lower extremities, back, or arms.
The epidermis was separated as described previously (8). Specif-
ically, the epidermis was separated from whole-skin biopsies
by overnight incubation at 4℃ in a 1:1 (v/v) mixture of
Dispase solution (Roche Molecular Biochemicals, Manheim,
Germany) and Hank’s balanced salt solution (HBSS; Gibco
BRL, Life Technologies, Rockville, MD, U.S.A.).
Assessing the clinical severity of psoriasis
The clinical severity was assessed using the PASI score,
which is calculated as follows: 
PASI=0.1 (Eh+Ih+Dh)Ah+0.2 (Eu+Iu+Du)Au+0.3 (Et+It+
Dt)At+0.4 (El+Il+Dl)Al, where E=erythema, I=infiltration,
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Ceramides and Cell Signaling Molecules in Psoriatic Epidermis:
Reduced Levels of Ceramides, PKC- , and JNK
Ceramides are the main lipids in the stratum corneum and are generated during
cellular stress and apoptosis by de novo synthesis or by the action of sphingomyeli-
nase. In addition, they are lipid second messengers produced by sphingolipid meta-
bolism and trigger important cell responses, including protein kinase C-alpha (PKC- )
activation and the stimulation of signal transduction pathways with apoptosis and
stress-activated protein kinases (SAPK), such as c-jun N-terminal kinase (JNK).
Thus, ceramides have anti-proliferative and apoptotic effects. This study measured
the changes in the levels of epidermal ceramides and ceramide-related apoptotic
signaling molecules in psoriasis patients. Samples from lesional and non-lesional
epidermis were obtained from psoriasis patients. Total ceramides were fractionat-
ed using thin-layer chromatography, and the levels of PKC- and JNK expression
were measured using Western blot analysis with specific antibodies. The ceramide
level was reduced significantly, and this was associated with the downregulation
of apoptotic signaling molecules, such as PKC- and JNK, in the lesional epidermis
of psoriasis patients. These results suggest that the decreased level of ceramides
downregulates the apoptotic pathway, leading to epidermal proliferation in psoriasis.
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D=desquamation, A=area, h=head, u=upper extremities,
t=trunk, and l=lower extremities. A numerical value is given
to the extent of the lesions in each area: 1=<10%, 2=10-30%,
3=30-50%, 4=50-70%, 5=70-90%, and 6=90-100%. E,
I, and D are scored on a five-point scale (0=no symptoms,
1=slight, 2=moderate, 3=marked, and 4=very marked) to
obtain a final PASI score between 0 and 72. The PASI scores
of the patients who took part in this study ranged between
4.9 and 20.7; this range corresponds to mild and moderate
psoriasis. Only patients with PASI scores <25 were enrolled
in this study in order to determine whether alterations in
the levels of ceramides and ceramide-related apoptotic sig-
naling molecules are closely correlated to the clinical severi-
ty in mild to moderate psoriasis.
Measuring ceramide levels
The frozen skin samples were added to 600  L of Folch
solution (CHCl3: MeOH [2:1, v/v] mixture) and were homo-
genized using a polytron homogenizer, and 200  L of 0.1 M
KCl were added. The mixture was centrifuged at 12,000
rpm twice for 5 min each. The lower phase containing the
extracted lipids was fractionated by thin-layer chromatogra-
phy (TLC) on 0.20 mm silica gel 60-coated plates (10×10
cm plate, Whatman Inc., Clifton, NJ, U.S.A.) using a mod-
ification of the method reported by Uchida et al. (8-10). Spe-
cifically, after depositing each sample on the plate, it was
developed first up to 5.0 cm using a mobile phase consist-
ing of CHCl3:MeOH:H2O (57:12:0.6, v/v/v) and then up to
14.0 cm using 1,2-dichloroethane:CHCl3:acetic acid (46:6:
0.05, v/v/v). The latter step was repeated using the same
mobile phase. Finally, the chromatogram was developed to
the top using a mobile phase consisting of n-hexane:diethy-
lether:acetic acid (98:1:1, v/v/v). All these solvents were ob-
tained from Sigma-Aldrich. Each stage of development was
carried out after the plate was air-dried completely. The UV
absorbance of the fractions containing total ceramides was
measured at 254 nm using a TLC scanner. The data were
analyzed using the program winCAT (TLC scanner; CAMAG
winCATS TLC scanner 3, 254 nm).
To allow for variation in the absolute value among sub-
jects, the ceramide content was normalized according to the
protein content. The upper phase of the lipid extraction stage
was centrifuged at 800×g for 5 min to remove tissue debris,
and the protein concentration was determined according to
the modified Lowry method using bovine serum albumin as
a standard (11). The levels of ceramides were assessed as cpm/
g protein.
Antibodies
The primary antibodies against PKC- , ceramidase, and
JNK were isotype mouse IgG2b, IgG1, and isotype rabbit
IgG, respectively. Anti-PKC- and anti-ceramidase were
obtained from BD Bioscience, and anti-JNK was from Santa
Cruz Biotechnology. All secondary antibodies were obtained
from Amersham Biosciences.
Expression of PKC- , JNK, and ceramidase
Soluble fractions were prepared from psoriatic epidermis,
and equal amounts of protein (50  g) were resolved on 8%
gels by using sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). The proteins were transferred to
nitrocellulose membranes and blotted with specific antibodies
to PKC- , JNK, and ceramidase, using standard procedures.
PKC, JNK, and ceramidase/antibody complexes were visu-
alized by autoradiography using a chemiluminescent sub-
strate. The optical densities were measured using a densito-
meter and were normalized using a control. All procedures
were performed in triplicate.
Statistical analysis
The statistical significance of the differences in the levels
of ceramides, PKC- , JNK, and ceramidase between lesion-
al and non-lesional samples of psoriasis patients was assessed
using a paired t-test. The correlations between the levels of
ceramides, PKC- , JNK, and ceramidase and the PASI scores
were determined using the Pearson correlation test. p-values
<0.05 were considered statistically significant.
RESULTS
The level of ceramides in psoriatic epidermis
The levels of ceramides in lesional and non-lesional epider-
mis and the PASI scores of the psoriasis patients are shown
in Table 1. Although the absolute level of ceramides differed
among the patients, the level of ceramides in the lesional
epidermis was always significantly lower (n=5, p<0.05) than
that in the non-lesional epidermis, with the percentage reduc-
tion ranging from 21.7 to 75.8. A highly significant posi-
tive correlation was observed between the percentage reduc-
tion of the ceramide level and the PASI score (r=0.944, p=
0.016), as shown in Fig. 1, indicating that the ceramide level
is inversely correlated with the PASI score in mild to mod-
erate psoriasis.
Western blot analysis
The expression levels of PKC- , JNK, and ceramidase were
measured in both lesional and non-lesional epidermis. The
expression of PKC- was not detected in lesional epidermis,
in contrast to the expression in non-lesional epidermis (Fig.
2). The expression level of JNK was lower in lesional epider-
mis than in non-lesional epidermis. Although the absoluteCeramides and Apoptotic Signaling Molecules in Psoriatic Epidermis 97
level of JNK expression differed among the subjects, the
expression levels in lesional epidermis were always significantly
lower than those in non-lesional epidermis (p<0.05) (Fig. 3).
However, no correlation was observed between the reductions
in the PKC- and JNK levels and the PASI score (data not
shown). The expression of ceramidase was much lower in
both lesional and non-lesional epidermis, and the differences
between the two were insignificant (data not shown).
DISCUSSION
Decreased levels of ceramides have been reported in skin
conditions involving dryness and barrier disruption, such as
psoriasis. Moreover, the importance of ceramides in the epi-
dermal lipid barrier has been documented repeatedly (1, 3-
5). In terms of the apoptotic pathway, however, there are few
investigations of ceramides and related apoptotic signals in
psoriatic epidermis. This study showed that the level of cera-
mides was significantly reduced with concomitant decreases
in PKC- and JNK in lesional epidermis of patients with
psoriasis.
Decreased levels of ceramides have been associated with
skin conditions involving dryness and barrier disruption,
such as psoriasis, atopic dermatitis, and xerosis (12, 13). In
this study, the levels of ceramides were decreased significantly
in psoriatic epidermis. The level of ceramides in the epider-
mis results from the balance between the activities of cera-
mide-generating enzymes, such as serine palmitoyl transferase
in the de novo synthesis pathway and sphingomyelinase, and
the activities of degradative enzymes, such as ceramidase (14-
17). Previously, we observed that the levels of ceramides were
Fig. 2. Western blot analysis of PKC- in lesional and non-lesional
epidermis of psoriasis patients. Western blotting was performed
using mouse anti-PKC- antibodies, as described in the Materials
and Methods. The level of PKC- expression was quantified by
densitometry (optical density, OD) and is expressed as the per-
centage of the expression of the control  -actin (normalized OD).
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Fig. 3. Western blot analysis of JNK in lesional and non-lesional
epidermis of psoriasis patients. Western blotting was performed
using rabbit anti-JNK antibodies, as described in the Materials
and Methods. The level of the JNK expression was quantified by
densitometry (optical density, OD) and is expressed as the per-
centage of the expression of the control  -actin (normalized OD).
*Significant differences between lesional epidermis and non-lesion-
al epidermis (p<0.05).
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*Significant difference between lesional epidermis and non-lesional epi-
dermis (n=5, p<0.05). 
�
The % reduction was calculated as [(non-lesional
level lesional level)/non-lesional level]×100.
Patient 
No.
% 
Reduction
�
PASI 
score
Ceramides (Area No./ g)
Lesional
epidermis
Non-lesional
epidermis
1 9.25 20.96 55.9 10.45
2 11.12 23.97 53.6 15.63
3 17.89 25.12 28.8 5
4 5.48 22.67 75.8 20.7
5 15.21 19.42 21.7 4.9
Mean 11.79±4.89* 22.43±2.29
Table 1. The levels of ceramides in lesional and non-lesional
epidermis of psoriasis patients
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Fig. 1. Correlation between the percentage reduction in the cera-
mide level in lesional epidermis and the PASI scores of psoriasis
patients. A highly significant positive correlation was observed
between the percentage reduction of the ceramide level and the
PASI score (r=0.944, p=0.016).98 B.-L. Lew, Y. Cho, J. Kim, et al.
decreased, while those of diacylglycerol were increased (13).
In addition, no alteration in the ceramidase level was detect-
ed. It is understood that the sphingomyelin pathway is ini-
tiated by the hydrolysis of sphingomyelin by sphingomyeli-
nase (18). Together with these findings, the present data
suggest that the dramatic reduction in the ceramide level,
which is significantly correlated with the clinical severity, is
caused by a decrease in the activity of sphingomyelinase.
However, the complete relationship between the ceramide
content and the activity of ceramide-metabolizing enzymes
in the psoriatic skin remains to be clarified.
We observed decreased levels of PKC- and JNK expres-
sion in lesional epidermis with psoriasis, together with decre-
ased levels of ceramides. This suggests that the decreased
level of ceramides induced downregulation of the apoptotic
signaling pathway in the psoriatic epidermis. These results
are in concordance with the findings of earlier studies, in
which the level of PKC- expression was decreased in psori-
atic epidermis (19, 20). However, no correlation was observed
between the expression levels of PKC- and JNK and the
PASI score in mild to moderate psoriasis.
Ceramides induce the activation of apoptotic cell-signal-
ing molecules, such as PKC- and JNK. In addition, sph-
ingomyelinase-induced ceramide generation is stimulated
by PKC- and JNK activation (20, 21). Hence, this suggests
that decreased ceramide levels lead to the downregulation of
PKC- and JNK, which in turn downregulates sphingomyeli-
nase-induced ceramide generation and ultimately induces
the anti-apoptotic and proliferative characteristics of psori-
atic epidermis.
In conclusion, we demonstrated that 1) the level of cera-
mides was reduced significantly in lesional epidermis with
psoriasis, 2) this decrease was associated with the downreg-
ulation of apoptotic signaling molecules, such as PKC- and
JNK, and 3) there was a significant correlation between the
ceramide level and the clinical severity in mild to moderate
psoriasis. We are not certain whether this finding is a pri-
mary or secondary event in psoriasis. However, we suggest
that the reduction in the ceramide level not only induces a
defect in water retention and barrier function but also asso-
ciates with downregulation of the apoptotic pathway result-
ing in epidermal proliferation in psoriasis.
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